Immunotherapy in colorectal cancer: rationale, challenges and potential

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Nature reviews: Gastroenterology & hepatology

• Publication date

  2019-03-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41575-019-0126-xPMID 30886395PMCID PMC7295073
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor mutational load predicts survival after immunotherapy across multiple cancer types

  2019cited by this paper
• Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer.

  2018cited by this paper
• International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

  2018cited by this paper
• Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).

  2018cited by this paper
• Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

  2018cited by this paper
• Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities

  2018cited by this paper
• Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer.

  2018cited by this paper
• Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.

  2018cited by this paper
• Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.

  2018cited by this paper
• Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

  2018cited by this paper
• A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).

  2018cited by this paper
• CAR T-cell Therapy: A New Era in Cancer Immunotherapy.

  2018cited by this paper
• Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer.

  2018cited by this paper
• CAR T-cell Therapy for Solid Tumors?

  2018cited by this paper
• In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy

  2017cited by this paper
• Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data.

  2017cited by this paper
• Immunotherapy for Colorectal Cancer

  2017cited by this paper
• Tumour-associated macrophages as treatment targets in oncology

  2017cited by this paper
• Progress in tumor-associated macrophage (TAM)-targeted therapeutics.

  2017cited by this paper
• Companion and Complementary Diagnostics–Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non–Small Cell Lung Cancer

  2017cited by this paper
• Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

  2017cited by this paper
• Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502).

  2017cited by this paper
• PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity

  2017cited by this paper
• Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

  2017cited by this paper
• Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?

  2017cited by this paper
• 484PDAnalysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) + ipilimumab (IPI): CheckMate 142

  2017cited by this paper
• Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.

  2017cited by this paper
• Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers.

  2017cited by this paper
• CAR T Cell Therapy for Solid Tumors.

  2017cited by this paper
• 403PPhase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC)

  2017cited by this paper
• Central evaluation for surgical treatment options in FIRE-3- updated results and impact on overall Survival.

  2017cited by this paper
• Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.

  2017cited by this paper
• Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

  2017cited by this paper
• Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC).

  2017cited by this paper
• MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.

  2016cited by this paper
• Abstract A006: Frameshift peptide neoantigens as vaccine targets in microsatellite-unstable cancers

  2016cited by this paper
• Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

  2016cited by this paper
• The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

  2016cited by this paper
• Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.

  2016cited by this paper
• Abstract 2651: Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma

  2016cited by this paper
• Cancer Immunology: Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

  2016cited by this paper
• The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

  2016cited by this paper
• Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).

  2016cited by this paper
• Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

  2016cited by this paper
• Conservation of immune gene signatures in solid tumors and prognostic implications

  2016cited by this paper
• The Immune Biology of Microsatellite-Unstable Cancer.

  2016cited by this paper
• Classification and characterization of microsatellite instability across 18 cancer types

  2016cited by this paper
• Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.

  2016cited by this paper
• Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

  2016cited by this paper
• Programmed death-1 blockade in mismatch repair deficient colorectal cancer.

  2016cited by this paper
• T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

  2016cited by this paper
• Abstract LB-264: Landscape of tumor-infiltrating T-cell repertoire of human cancers

  2016cited by this paper
• Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.

  2016cited by this paper
• Driving gene-engineered T cell immunotherapy of cancer

  2016cited by this paper
• Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.

  2016cited by this paper
• The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

  2015cited by this paper
• Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy.

  2015cited by this paper
• Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Regulation of tumour necrosis factor signalling: live or let die

  2015cited by this paper
• Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

  2015cited by this paper
• Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.

  2015cited by this paper
• ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes

  2015cited by this paper
• Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer

  2015cited by this paper
• The future of immune checkpoint therapy

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• The Consensus Molecular Subtypes of Colorectal Cancer

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Molecular and genetic properties of tumors associated with local immune cytolytic activity.

  2015cited by this paper
• PD-1 Restrains Radiotherapy-Induced Abscopal Effect

  2015cited by this paper
• Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

  2015cited by this paper
• Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases

  2015cited by this paper
• Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  2015cited by this paper
• Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).

  2015cited by this paper
• Mutant MHC class II epitopes drive therapeutic immune responses to cancer

  2015cited by this paper
• Adoptive cell transfer as personalized immunotherapy for human cancer

  2015cited by this paper
• Neoantigens in cancer immunotherapy

  2015cited by this paper
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

  2015cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• MSIsensor: microsatellite instability detection using paired tumor-normal sequence data

  2014cited by this paper
• Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

  2014cited by this paper
• Colorectal cancer statistics, 2014

  2014cited by this paper
• Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer.

  2014cited by this paper
• Germline variants in POLE are associated with early onset mismatch repair deficient colorectal cancer

  2014cited by this paper
• Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer.

  2014cited by this paper
• Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Microsatellite instability detection by next generation sequencing.

  2014cited by this paper
• Clinical targeting of the TNF and TNFR superfamilies

  2013cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING

  2013cited by this paper
• Current status of screening for colorectal cancer.

  2013cited by this paper

• Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next-Generation Approaches.

  2026cites this paper
• Chemokine CCL5 overexpression combined with radiotherapy modulates Th1-mediated immune response and leads to significant tumor growth delay in mouse tumor models.

  2026cites this paper
• IGSF9 promotes immunotherapy resistance in colon cancer by orchestrating an immunosuppressive tumor microenvironment and enables combinatorial targeting strategies.

  2026cites this paper
• TNF-α deficiency underlies NK cell dysfunction in colorectal cancer.

  2026cites this paper
• Identification of super-enhancer-based biomarkers for predicting survival and immunotherapy efficacy in colorectal cancer

  2026cites this paper
• Electroacupuncture Combined with Fruquintinib and Sintilimab in Microsatellite-Stable Metastatic Colorectal Cancer: A Phase II Study.

  2026cites this paper
• Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial

  2026cites this paper
• Curcumin enhances GSDME-mediated pyroptosis to potentiate PD-1/PD-L1 immune checkpoint blockade in colorectal cancer

  2026cites this paper
• HOXD13-mediated immune crosstalk between cancer cells and tumor-associated macrophages drives colorectal cancer progression

  2026cites this paper
• Research Progress on Tumor-Associated Macrophages and PD-1/PD-L1 Inhibitors in Advanced Colorectal Cancer.

  2026cites this paper
• Vitamin C in the Treatment of Colorectal Cancer: Between Hope and Despair.

  2026cites this paper
• Immunotherapy in advanced colorectal cancer: Current landscape, mechanisms, challenges, and future directions.

  2026cites this paper
• Circadian Clock Genes in Colorectal Cancer: From Molecular Mechanisms to Chronotherapeutic Applications

  2026cites this paper
• Identification of key ferroptosis-related targets in colorectal cancer: A transcriptomics-driven study via machine learning and AUcell analysis of single-cell RNA-sequencing

  2026cites this paper
• FTO-mediated m6A demethylation of CSF3 suppresses NETosis via downregulation of RLN2 expression in colorectal cancer

  2026cites this paper
• Tumor mutational burden predicts neoantigen profiles and immunotherapy response in microsatellite stable tumors across different cancer types

  2026cites this paper
• Napabucasin transforms liver microenvironment and boosts immunotherapy efficacy by converting potential metastases into “hot” tumors

  2026cites this paper
• Hot injection synthesis of metal-doped Ag2S nanocrystals: A novel multifunctional approach for cancer therapy, antibacterial strategies, and antioxidant defense

  2026cites this paper
• Identification of public neoantigens with broad HLA class I coverage as candidates for off-the-shelf cancer vaccine development in colorectal cancer.

  2026cites this paper
• Modulating the tumor immune phenotypes by radiotherapy: formulating and validating the combination therapy of radiation, PD-L1, and TIM-3 blockade in colorectal cancer

  2026cites this paper
• Enhancing gastric cancer immunotherapy: Insights from multi-omics analysis and innovations in photodynamic-chemotherapy nanoplatforms.

  2026cites this paper
• Beyond tumor mutational burden: a framework for immune-checkpoint blockade responsiveness in gastrointestinal cancers.

  2026cites this paper
• Tumor-specific antibody cocktail treatment suppresses colorectal tumor growth in mice

  2026cites this paper
• Artificial intelligence application in routine pathology: ChatGPT-4.0 and Gemini 2.5 pro performance in detection of MMR-deficiency in colorectal cancer.

  2026cites this paper
• Antibody-drug conjugates in colorectal cancer: advances in targeted delivery and personalized oncology.

  2026cites this paper
• SIAH2–WNK1 Signaling Drives Glycolytic Metabolism and Therapeutic Resistance in Colorectal Cancer

  2026cites this paper
• Unveiling the prognostic role of FABP4 in early-onset colorectal cancer through big data analysis and preliminary clinical validation

  2026cites this paper
• WNT-driven immune evasion promotes malignant transformation of BRAF-mutant colorectal cancer

  2026cites this paper
• Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer

  2026cites this paper
• Targeting HSPB1 inhibits tumor growth and abrogates Treg-mediated tumor immunosuppression.

  2026cites this paper
• Colorectal Cancer in Young Adults in Panama: Clinical, Molecular, and Epidemiological Characterization in a National Cohort

  2026cites this paper
• Emerging nano-immunotherapeutic strategies achieve metastatic colorectal cancer precision therapy

  2026cites this paper
• Memory B cell subset shapes antitumor immunity and response to PD-1 blockade in mismatch repair-deficient colorectal cancers

  2026cites this paper
• Risk and Management of Bowel Obstruction in Colorectal Cancer Patients Undergoing Immunotherapy: A Cross-Sectional Multicenter Study

  2026cites this paper
• Construction of a Platelet‐Related Gene Signature for Predicting Prognosis and Drug Sensitivity in Colorectal Cancer

  2026cites this paper
• Integrated 16S rRNA Sequencing and Metabolomics Analysis Reveal the Protective Effects of (E)-Flavokawain A on AOM/DSS-Induced Colorectal Cancer in Mice

  2026cites this paper
• Key immune cells in the tumor immune microenvironment of colorectal cancer: Roles and research advances (Review)

  2026influential citation
• Identification of necrosis-related signature for predicting prognosis and immunotherapy response in gastric cancer

  2026cites this paper
• CCL24 recruits CCR3+ TAMs to promote immunosuppression via YAP1 activation and serves as a therapeutic target for Gracillin in colorectal cancer

  2026cites this paper
• Enhancing Immunotherapy in Lung Cancer: The Promise of dMMR/MSI‐H Tumors and Immune Checkpoint Inhibitors

  2026cites this paper
• A multi-dimensional omics framework identifies GPR35 as a driver of M2 macrophage activation and poor prognosis in colorectal cancer.

  2026cites this paper
• Increasing the Response of Mismatch Repair Proficient Rectal Cancer to Immunotherapy with Particle Radiation and DNA Damage Response Inhibitors-Preclinical Evidence.

  2026cites this paper
• A novel risk model incorporating MMP9, TLR8, and LILRB2 drives neutrophil extracellular trap formation and promotes immune evasion in glioma.

  2026cites this paper
• Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancer

  2026cites this paper
• Glucose metabolism sustains aberrant STAT3 signaling in colorectal cancer through glycosylated local signaling factors.

  2026cites this paper
• Single-Cell Transcriptomic Landscape of Right-Sided Colon Cancer Reveals Cellular and Molecular Features of Metastatic Potential

  2026cites this paper
• Antigen Remodeling in Colorectal Cancer: How Radiotherapy and Chemotherapy Enhance Immunotherapy Responsiveness.

  2026cites this paper
• Research trends of tumor-associated macrophages in colorectal cancer: a bibliometric analysis.

  2026cites this paper
• A case report and literature review of duodenal adenocarcinoma with complete loss of mismatch repair proteins.

  2026cites this paper
• Cuproptosis and Disulfidptosis Converge to Empower PD-L1 Checkpoint Therapy via Cadict-Induced PD-L1 Translation.

  2026cites this paper
• Advances in immunotherapy for colorectal cancer: overcoming resistance in mismatch repair-proficient tumors.

  2026cites this paper
• Endothelial cell-derived IGFBP7 suppresses angiogenesis and tumor progression in colorectal cancer via the VAPA-TGF-β1 pathway.

  2026cites this paper
• Disparities in Tumor Microenvironment Between Primary and Metastatic Colorectal Cancer: Impact on Immune Infiltration and Survival.

  2026cites this paper
• Inulin-Based Oral Chemotherapy Modulates Gut Microbiota and Immune Microenvironment through Inhibition of Neutrophil Extracellular Trap Formation for Improving Cancer Therapy.

  2026cites this paper
• DNA methylation-mediated extracellular matrix gene silencing in colorectal cancer.

  2026cites this paper
• Reference-free microsatellite instability detection from tumor sequencing using intrasample variability modeling

  2026cites this paper
• Radiomic signatures from baseline CT predict chemotherapy response in unresectable colorectal liver metastases

  2026cites this paper
• Caffeic acid restores the M1-polarized immune balance but decreases IgG and IgM levels in human colorectal cancer HT-29 cell-bearing nude mice.

  2026cites this paper
• Network pharmacology combined with transcriptomics reveals that Ganoderma lucidum spore and Sanghuangporus vaninii compound extract exerts anti-colorectal cancer effects via CYP24A1-mediated VDR pathway and TERT-mediated Wnt signaling pathway.

  2025cites this paper
• Artificial intelligence in colorectal cancer liver metastases: From classification to precision medicine.

  2025cites this paper
• High‑dose sodium propionate contributes to tumor immune escape through the IGF2BP3/PD‑L1 axis in colorectal cancer

  2025cites this paper
• NCOA3 impairs the efficacy of anti-PD-L1 therapy via HSP90α/EZH2/CXCL9 axis in colon cancer.

  2025cites this paper
• Research Progress in the Regulatory Mechanisms of Lactylation in Tumor Development and Therapy

  2025cites this paper
• Exploring the Role of Cellular Interactions in the Colorectal Cancer Microenvironment

  2025cites this paper
• CCT8 drives colorectal cancer progression via the RPL4-MDM2-p53 axis and immune modulation

  2025cites this paper
• Safety, efficacy, and cost-effectiveness evaluation of systemic treatments for refractory colorectal cancer: a systematic review and modeling study

  2025cites this paper
• Self-Assembled Glycopeptide as a Biocompatible mRNA Vaccine Platform Elicits Robust Antitumor Immunity.

  2025cites this paper
• Advanced Technologies for Cancer Immunotherapy: Focus on Gastrointestinal Cancers.

  2025cites this paper
• HOXC6 promotes the metastasis of MSI-H CRC by interacting with M2 macrophages and inducing effector T cell exhaustion

  2025cites this paper
• Endoplasmic reticulum stress-related prognosis signature characterizes the immune landscape and predicts the prognosis of colon adenocarcinoma

  2025cites this paper
• Carnitine palmitoyltransferase 2 as a novel prognostic biomarker and immunoregulator in colorectal cancer.

  2025cites this paper
• Robotic-assisted colorectal surgery in colorectal cancer management: a narrative review of clinical efficacy and multidisciplinary integration

  2025cites this paper
• Construction of a Prognostic Model based on CSC-related Genes in Patients with Colorectal Cancer

  2025cites this paper
• Integrating network pharmacology and experimental validation to uncover the synergistic effects of Huangqi ()-Ezhu () with 5-fluorouracil in colorectal cancer models.

  2025cites this paper
• The Dynamic Changes of Circulating Myeloid-Derived Suppressor Cells (MDSCs) Subsets in Colorectal Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy

  2025cites this paper
• NSUN2 promotes colorectal cancer progression and increases lapatinib sensitivity by enhancing CUL4B/ErbB‐STAT3 signalling in a non‐m5C manner

  2025cites this paper
• Addressing Challenges in Targeted Therapy for Metastatic Colorectal Cancer

  2025cites this paper
• The Role of Inorganic Nanomaterials in Overcoming Challenges in Colorectal Cancer Diagnosis and Therapy

  2025cites this paper
• Comprehensive identification of a migrasomes-associated long non-coding RNA signature to predict the prognosis and treatment options in colon adenocarcinoma

  2025cites this paper
• Understanding the cellular and molecular heterogeneity in colorectal cancer through the use of single-cell RNA sequencing

  2025cites this paper
• Methionine Metabolism Dictates PCSK9 Expression and Antitumor Potency of PD‐1 Blockade in MSS Colorectal Cancer

  2025cites this paper
• The role of tumor-associated fibroblast-derived exosomes in chemotherapy resistance of colorectal cancer and its application prospect.

  2025cites this paper
• A protease-cleavable liposome for co-delivery of anti-PD-L1 and doxorubicin for colon cancer therapy in mice

  2025cites this paper
• Efficacy of combined immunotherapy and targeted therapy in overcoming barriers to postoperative recurrence in squamous subtype anaplastic thyroid carcinoma with abscess: a case report and literature review

  2025cites this paper
• Colorectal cancer cell‐derived extracellular vesicles trigger macrophage production of IL6 through activating STING signaling to drive metastasis

  2025cites this paper
• Upregulation of RIG‐I is Critical for Responsiveness to IFN‐α Plus Anti‐PD‐1 in Colorectal Cancer

  2025cites this paper
• Current status of multiple markers in precision immunotherapy for colorectal cancer

  2025cites this paper
• PAR2 deficiency impairs antitumor immunity and attenuates anti-PD1 efficacy in colorectal cancer.

  2025cites this paper
• Insights from the bottom-up development of LGR5-targeting immunotherapeutics

  2025cites this paper
• Clinical management of checkpoint inhibitor pneumonitis: Focus, challenges, and future directions

  2025cites this paper
• Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer

  2025cites this paper
• Comprehensive immunophenotyping reveals distinct tumor microenvironment alterations in anti-PD-1 sensitive and resistant syngeneic mouse model

  2025cites this paper
• CD47 as a potent target in cancer immunotherapy: A review.

  2025cites this paper
• Quercetin's Potential Therapeutic Role in Human Colorectal Cancer: An Effective Strategy for Prevention and Treatment.

  2025cites this paper
• BRAF mutation cancer, colorectal cancer, tumor associated lymph node structure and immune microenvironment study: MAPK protein kinase molecular action and SIRPG-CD47 protein signaling pathway.

  2025cites this paper
• Therapeutic potential of fecal microbiota transplantation in colorectal cancer based on gut microbiota regulation: from pathogenesis to efficacy

  2025cites this paper
• Site-dependent Treg cell transcriptional reprograming in a metastatic colorectal cancer model holds prognostic significance

  2025cites this paper
• Sprayed hyaluronic acid based multidrug composite hydrogel for postoperative colorectal cancer ultra-efficient long-lasting multi-stage immuno-chemo synergistic therapy.

  2025cites this paper
• Survival analysis and prediction of early-onset colorectal cancer patients post-chemotherapy: an analysis based on the SEER database

  2025cites this paper
• CLINICAL DEVELOPMENT OF IMMUNO-ONCOLOGY THERAPEUTICS.

  2025cites this paper